The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.
这项发明涉及一种名为卤化康柏斯塔汀(halocombstatins)的新化合物。卤化康柏斯塀是康柏斯塀A-3的衍
生物,包括对一系列人类癌
细胞系和小鼠P388白血病表现出癌细胞生长抑制作用的化合物,以及作为微管聚合
抑制剂和结合
秋水仙碱对微管的
抑制剂的活性。